top of page


Press releases


Oral formulation of Nanoligomer treatments is Protective in Autoimmune (Colitis) Disease: Findings Published in ACS Pharmacology & Translational Science
Autoimmune and autoinflammatory diseases affect millions of people in the U.S., and among these, inflammatory bowel diseases (IBD) like...
Aug 31, 2024


The Future is Here: Sachi Bio Advances Space-based Drug Discovery
In the realm of pharmaceuticals, the pursuit of innovation knows no bounds. Scientists and researchers constantly strive to leverage...
Aug 15, 2024


Sachi Bio's Nanoligomers Reduce Space-induced Disease Pathology: Findings Published in ACS Chemical Neuroscience
Space travel has long fascinated humanity, but it also poses significant health risks, particularly to the brain and muscles. The...
Jul 31, 2024


Sachi Bio wins NASA Phase IIE and III contracts to Develop Neuroprotective Countermeasures for Long-term Space travel
Sachi Bio won Phase IIE and Phase III contracts from the NASA Human Research Program to continue advancement of the Neurotherapeutic...
Apr 15, 2024


Investigational New Drug (IND)-enabling Studies for Sachi Bio's lead molecule
Sachi Bio's lead program NI112 shows excellent Safety-Toxicity, brain-delivery, and biodistribution profile in Investigational New Drug...
Mar 31, 2024


Sachi Bio lead shows Effect in Multiple Sclerosis Model: Findings published in ACS Chemical Neuroscience
Multiple sclerosis (MS) is a serious autoimmune disease that affects millions of people worldwide, with women being four times more...
Mar 25, 2024


Nanoligomer Lead is Neuroprotective in Protein Misfolding Prion Disease: Findings published in ACS Chemical Neuroscience
Neuroinflammation, or inflammation in the brain, plays a significant role in many neurodegenerative diseases. These diseases, which...
Mar 20, 2024


Sachi Bio lead programs to support NASA Missions & counter debilitating diseases on Earth
"Sachi Bio has successfully advanced it's lead program towards translation for a range of neurodegenerative diseases, as well as a...
Jan 31, 2024


Subscribe to Our Newsletter
bottom of page

